NCT06479954ACTIVE_NOT_RECRUITING

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

ELREXFIO SPECIAL INVESTIGATION- INVESTIGATION ON LONG-TERM TREATMENT -

Sponsor: Pfizer

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Study type

OBSERVATIONAL

Conditions

Relapsed and Refractory Multiple Myeloma (RRMM)

Interventions

—

Enrollment

1 participants

Primary completion

Feb 2027

Study completion

Feb 2027

First posted

Jun 2024

Last updated

Oct 2025

Primary Endpoints (CT.gov)

Incidence of CRS events in adverse drug reaction

Time frame: up to 52 weeks

Incidence of ICANS events in adverse drug reaction

Time frame: up to 52 weeks

Secondary Endpoints

Proportion of patients with objective response rate (ORR)

Incidence of other adverse drug reactions (ADRs)

Eligibility Criteria

Inclusion Criteria: Patients who have received at least one dose of elranatamab.

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source